Combination treatment for advanced small cell lung cancer or other neuroendocrine cancers
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of two investigational drugs, obrixtamig and ZL-1310, for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of small cell lung cancer, large cell neuroendocrine lung cancer, or extrapulmonary neuroendocrine carcinoma (cancers that start in hormone-producing cells outside the lungs).
- If your cancer has mixed cell types, at least half of the tumor must be the neuroendocrine component.
- You must have already tried at least one line of platinum-based chemotherapy (like cisplatin or carboplatin), unless you have a medical reason not to.
- You must be 18 years or older and willing to follow the study schedule and procedures.
- You cannot have certain previous treatments (like drugs targeting DLL3) or more than 30 Gy of radiation to the chest.
- You must not have cancer that has spread to the lining of the brain (leptomeningeal disease) or have had an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests whether adding a new drug, obrixtamig, to the usual first treatment for extensive-stage small cell lung cancer can help people live longer or slow the cancer's growth. The usual treatment is a combination of atezolizumab, carboplatin, and etoposide.
This trial tests a new drug for people with a rare type of lung cancer called large-cell neuroendocrine carcinoma (LCNEC). It is for those with advanced cancer that can't be cured, and who have just started standard chemotherapy. The drug is given after one cycle of chemo and may help control the cancer.
This trial tests two new immunotherapy drugs (obrixtamig and pumitamig) given together for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and helps shrink or control the cancer.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.